Literature DB >> 2280209

Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice.

C Gillespie1, L C Read, C J Bagley, F J Ballard.   

Abstract

The relative potencies of insulin-like growth factor (IGF-I) and the N-terminal truncated derivative, des(1-3)IGF-I, have been compared in lit/lit mice. Injection of 30 micrograms IGF-I, 30 micrograms des(1-3)IGF-I or 3 micrograms des(1-3)IGF-I daily for 3 weeks increased total length and nose-rump length of the animals substantially more than in controls or animals treated with 3 micrograms IGF-I daily. Body weight changes were not statistically significant. The lower dose of des(1-3)IGF-I, but not that of IGF-I, led to increases in kidney and heart weights relative to controls, while the higher dose of either IGF-I or des(1-3)IGF-I also increased the weights of liver, lungs and stomach. These results indicate that the higher potency of des(1-3)IGF-I demonstrated in cultured cells also applies in vivo to at least one strain of GH-deficient animals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280209     DOI: 10.1677/joe.0.1270401

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  2 in total

Review 1.  Insulin-like growth factor 1 physiology: lessons from mouse models.

Authors:  Shoshana Yakar; Martin L Adamo
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

2.  Unbound (bioavailable) IGF1 enhances somatic growth.

Authors:  Sebastien Elis; Yingjie Wu; Hayden-William Courtland; Dara Cannata; Hui Sun; Mordechay Beth-On; Chengyu Liu; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Jelena Basta-Pljakic; Luis Cardoso; Clifford J Rosen; Jan Frystyk; Shoshana Yakar
Journal:  Dis Model Mech       Date:  2011-05-31       Impact factor: 5.758

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.